Ποια είναι η τιμή για POINT Biopharma Global Inc. (PNT)

Η τιμή για POINT Biopharma Global Inc. (PNT) είναι $12.50

Ποια είναι η κεφαλαιοποίηση αγοράς για POINT Biopharma Global Inc. (PNT)

Η κεφαλαιοποίηση αγοράς για POINT Biopharma Global Inc. (PNT) είναι $708.42M

POINT Biopharma Global Inc. (PNT) Διαίρεση Μετοχών

POINT Biopharma Global Inc. functions as a radiopharmaceutical company dedicated to the advancement and commercialization of specialized radioligand therapies designed to combat various cancerous conditions. Its two primary investigational treatments, both currently in Phase III clinical trials, are PNT2002, a radioligand engineered to target prostate-specific membrane antigen (PSMA) for addressing metastatic castration-resistant prostate cancer, and PNT2003, a somatostatin-targeted radioligand being evaluated for the treatment of neuroendocrine tumors. Beyond these late-stage programs, the company's pipeline includes earlier-stage product candidates such as PNT2001, a next-generation PSMA-targeting agent undergoing preclinical studies for non-metastatic castration-sensitive prostate cancer, and PNT-2004, a program focused on fibroblast activation protein-alpha (FAP-a) with broad potential across multiple tumor types, also in preclinical development. Additionally, POINT Biopharma is actively developing further drug candidates utilizing its CanSEEK technology, which it has sub-licensed from Bach Biosciences LLC and Avacta Life Sciences Limited. The company was established in 2019 and is headquartered in Indianapolis, Indiana.